


Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional) 18086 (PC27339A)		Application Number 10/533,017																																									
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		Applicant(s) Maria Cristina Geroni, et al.																																											
		Filing Date April 28, 2005		Group Art Unit Unassigned																																									
		FOREIGN PATENT DOCUMENTS <table border="1"> <thead> <tr> <th rowspan="2">REF</th> <th rowspan="2">DOCUMENT NUMBER</th> <th rowspan="2">DATE</th> <th rowspan="2">COUNTRY</th> <th rowspan="2">CLASS</th> <th rowspan="2">SUBCLASS</th> <th colspan="2">TRANSLATION</th> </tr> <tr> <th>YES</th> <th>NO</th> </tr> </thead> <tbody> <tr> <td>/M.F./</td> <td>1 088 900 A1</td> <td>4/4/01</td> <td>EPO</td> <td></td> <td></td> <td>√</td> <td></td> </tr> <tr> <td>/M.F./</td> <td>WO 01/58444 A1</td> <td>8/16/01</td> <td>PCT</td> <td></td> <td></td> <td>√</td> <td></td> </tr> <tr> <td>/M.F./</td> <td>WO 02/088714 A2</td> <td>11/7/02</td> <td>PCT</td> <td></td> <td></td> <td>√</td> <td></td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>				REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		YES	NO	/M.F./	1 088 900 A1	4/4/01	EPO			√		/M.F./	WO 01/58444 A1	8/16/01	PCT			√		/M.F./	WO 02/088714 A2	11/7/02	PCT			√							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS							TRANSLATION																																	
						YES	NO																																						
/M.F./	1 088 900 A1	4/4/01	EPO			√																																							
/M.F./	WO 01/58444 A1	8/16/01	PCT			√																																							
/M.F./	WO 02/088714 A2	11/7/02	PCT			√																																							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																																													
/M.F./	Fraier D. et al., "LC-MS-MS Determination of Nemorubicin (Methoxymorpholinyl)doxorubicin, PNU-152243A) and its 13-OH Metabolite (PNU-155051A) in Human Plasma", <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 30:377-389 (2002)																																												
/M.F./	Rivory L.P. et al., "Optimizing the Erythromycin Breath Test for Use in Cancer Patients", <i>Clinical Cancer Research</i> , 6:3480-3485 (2000)																																												
/M.F./	Rivory L.P. et al., "Hepatic Cytochrome P450 3A Drug Metabolism is Reduced in Cancer Patients Who Have an Acute-Phase Response", <i>British Journal of Cancer</i> , 87(3):277-280 (2002)																																												
/M.F./	Hirth J. et al., "The Effect of an Individual's Cytochrome CYP3A4 Activity on Docetaxel Clearance", <i>Clinical Cancer Research</i> , 6:1255-1258 (2000)																																												
/M.F./	Martinez C. et al., "Expression of Paclitaxel-Inactivating CYP3A Activity in Human Colorectal Cancer: Implications for Drug Therapy", <i>British Journal of Cancer</i> , 87(6):681-686 (2002)																																												
/M.F./	Quintieri L. et al., "In Vivo Antitumor Activity and Host Toxicity of Methoxymorpholinyl Doxorubicin: Role of Cytochrome P450 3A", <i>Cancer Research</i> , 60:3232-3238 (2000)																																												
EXAMINER /Meghan Finn/		DATE CONSIDERED 08/01/2007																																											
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																																													



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No. (Optional) 18086 (PC27339A)	Application Number 10/533,017
		Applicant(s) Maria Cristina Geroni, et al.	
		Filing Date April 28, 2005	Group Art Unit Unassigned
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
/M.F./		Nelson D.R. et al., "P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers and Nomenclature", <i>Pharmacogenetics</i> , 6:1-42 (1996)	
/M.F./		de Waziers et al., "Cytochrome P450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 253(1):387-394 (1990)	
/M.F./		Chang T.K.H. et al., "Differential Activation of Cyclophosphamide and Ifosfamide by Cytochromes P-450 and 3A in Human Liver Microsomes", <i>Cancer Research</i> , 53:5629-5637 (1993)	
/M.F./		Kivistö K.T. et al., "The Role of Human Cytochrome P450 Enzymes in the Metabolism of Anticancer Agents: Implications for Drug Interactions", <i>British Journal of Clinical Pharmacology</i> , 40:523-530 (1995)	
/M.F./		Shimada T. et al., "Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals: Studies with Liver Microsomes of 30 Japanese and 30 Caucasians", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 270(1):414-423 (1994)	
/M.F./		Murray A. et al., "Study of the Immunohistochemistry and T Cell Clonality of Enteropathy-Associated T Cell Lymphoma", <i>American Journal of Pathology</i> , 146(2):509-519 (1995)	
/M.F./		Waxman D.J. et al., "P450 Gene Induction by Structurally Diverse Xenochmeicals: Central Role of Nuclear Receptors CAR, PXR, and PRAR", <i>Archives of Biochemistry and Biophysics</i> , 369(1):11-23 (1999)	
/M.F./		Geroni C. et al., "Methoxymorpholinyl dx (FCE23762, PNU152243) Metabolism: Isolation, Structure Identification, and Biological Characterization of Active Metabolites", <i>Proceedings of the American Association for Cancer Research</i> , 38:234 (1997)	
EXAMINER /Meghan Finn/		DATE CONSIDERED 08/01/2007	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			